BIOHAVEN LTD (BHVN)

VGG1110E1079 - Common Stock

50.04  -0.84 (-1.65%)

After market: 50.04 0 (0%)

News Image
a month ago - Investor's Business Daily

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy

The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.

News Image
a month ago - Biohaven Ltd.

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
a month ago - Biohaven Ltd.

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
a month ago - Biohaven Ltd.

Biohaven Announces Proposed Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

News Image
a month ago - Biohaven Ltd.

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally...

News Image
a month ago - Market News Video

BHVN Crosses Above Key Moving Average Level

News Image
a month ago - Investor's Business Daily

Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease

The company is hoping to soon file for approval of what could be the first SCA treatment.

News Image
a month ago - Biohaven Ltd.

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale...

News Image
2 months ago - Biohaven Ltd.

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE...

News Image
2 months ago - Market News Video

Notable Thursday Option Activity: NOV, BHVN, SIG

News Image
3 months ago - Investor's Business Daily

Biohaven Stock Earns Relative Strength Rating Upgrade

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

News Image
3 months ago - InvestorPlace

BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024

BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024.

News Image
3 months ago - BusinessInsider

BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biohaven (NYSE:BHVN) just reported results for the second quarter of 2024.Bioha...

News Image
3 months ago - Biohaven Ltd.

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of...

News Image
3 months ago - Market News Video

Biohaven(BHVN) Shares Cross Above 200 DMA

News Image
4 months ago - Market News Video

Friday 7/19 Insider Buying Report: ADVM, BHVN

News Image
4 months ago - InvestorPlace

The 3 Smartest Healthcare Stocks to Buy With $1K Right Now

The healthcare stocks to buy deserve more respect from investors who seek top-level growth outside of the tech sector.

News Image
5 months ago - Market News Video

Thursday 6/20 Insider Buying Report: XOM, BHVN

News Image
5 months ago - Market News Video

Friday 5/31 Insider Buying Report: EXEL, BHVN